Oncology Central

Clinical management of metastatic kidney cancer: the role of new molecular drugs

0

Over the last few years, the most recent advances of the molecular mechanisms involved in renal cell carcinoma have led to the use of new drugs targeting VEGF, such as bevacizumab plus interferon, sorafenib, sunitinib, pazopanib, and axitinib, or the mTOR, such as temsirolimus and everolimus.

To view restricted content, please:
Share:

Leave A Comment